Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 15, 2025 11:24 ET | Source: HMNC Holding GmbH

Ketabon Presents New Data Showing Antidepressant Effects of Oral Ketamine (KET01) Are Independent of Dissociation

Ketabon, a JV between HMNC and Develco, shared new post hoc Phase 2 data for oral ketamine (KET01) in treatment-resistant depression (TRD)
September 11, 2025 07:00 ET | Source: Denovo Biopharma

A Landmark Pivotal Study Applying Precision Medicine to Psychiatry with Denovo’s DB104 (liafensine) for Treatment-Resistant Depression Published in JAMA Psychiatry

A Landmark Pivotal Study Applying Precision Medicine to Psychiatry with Denovo’s DB104 for Treatment-Resistant Depression Published in JAMA Psychiatry
August 14, 2025 07:00 ET | Source: Denovo Biopharma

Denovo Biopharma LLC to Participate in Upcoming Investor Events

Denovo Biopharma LLC to Participate in Upcoming Investor Events
April 09, 2024 13:00 ET | Source: DelveInsight Business Research LLP

Treatment-Resistant Hypertension Market is Anticipated to Showcase Immense Growth by 2032, Predicts DelveInsight | Key Companies - Idorsia, Janssen Biotech, Quantum Genomics, CinCor Pharma, Ionis Pharmaceuticals, Vifor Pharma

New York, USA, April 09, 2024 (GLOBE NEWSWIRE) -- Treatment-Resistant Hypertension Market is Anticipated to Showcase Immense Growth by 2032, Predicts DelveInsight | Key Companies - Idorsia, Janssen...
October 19, 2023 13:00 ET | Source: DelveInsight Business Research LLP

Treatment-Resistant Depression Market to Observe Stunning Growth by 2032, Assesses DelveInsight | Key Companies to Watch Out - Navitor, Supernus, Novartis, Relmada, Beckley Psytech, COMPASS, Axsome, Celon Pharma

New York, USA, Oct. 19, 2023 (GLOBE NEWSWIRE) -- Treatment-Resistant Depression Market to Observe Stunning Growth by 2032, Assesses DelveInsight | Key Companies to Watch Out - Navitor, Supernus,...
May 01, 2023 18:52 ET | Source: PharmAla Biotech

PharmAla Biotech to form Australian Psychedelics Joint Venture with Vitura Health

CORTEXA TO BE THE LEADING SUPPLIER OF MDMA AND PSILOCYBIN IN AUSTRALIA VANCOUVER, British Columbia, May 01, 2023 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla”)(CSE: MDMA) is...
February 03, 2023 00:01 ET | Source: PharmAla Biotech

Australia Allows Prescription of MDMA and Psilocybin in Groundbreaking Regulatory Change

VANCOUVER, British Columbia, Feb. 03, 2023 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla”)(CSE: MDMA) applauds the Australian Therapeutic Goods Administration (TGA) in allowing for...
August 09, 2021 07:00 ET | Source: Axsome Therapeutics, Inc.

Axsome Therapeutics Announces AXS-05 Achieves Primary and Key Secondary Endpoints in the MERIT Phase 2 Trial in Treatment Resistant Depression

AXS-05 significantly delayed the time to relapse of depression compared to placebo (p=0.002, primary endpoint) AXS-05 significantly prevented relapse of depression over at least 6 months compared to...
December 02, 2020 06:00 ET | Source: Axsome Therapeutics, Inc.

Axsome Therapeutics Announces Positive Results from the COMET-TRD Trial of AXS-05 in Patients with Treatment Resistant Depression

Rapid and substantial improvement in depressive symptoms achieved by 44% of patients at 2 weeks, 67% at 6 weeks (MADRS response), and sustained with long-term treatment Rapid and substantial...
May 29, 2020 07:00 ET | Source: Axsome Therapeutics, Inc.

Axsome Therapeutics Presents Data from GEMINI Phase 3 Trial of AXS-05 in Major Depressive Disorder at the 2020 American Society for Clinical Psychopharmacology Annual Meeting

NEW YORK, May 29, 2020 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS)...